Abstract: This invention relates to a process for chemically treating a carbon-containing feedstock (e.g., a polymer-based feedstock), comprising contacting (e.g., by a hydrocracking reaction) the carbon-containing feedstock and a hydrogen stream in the presence of at least one hydrocracking catalyst to produce an alkane-containing product stream. The hydrocracking catalyst comprises at least one transition metal or transition metal sulfide supported on an oxide-containing support. This invention also relates to an alkane-containing mixture obtained by the process described herein and a system/apparatus for carrying out the process described herein.

Abstract: A process for the cracking of a carbon-containing feedstock to produce olefins, aromatics and/or aliphatic includes contacting, in a reactor system, the carbon-containing feedstock with oxygen gas in the presence of a molten salt matrix consisting of a eutectic mixture of alkali metal carbonates, alkali metal hydroxides, alkali metal nitrates, alkali metal halides, alkaline earth metal carbonates, alkaline earth metal hydroxides, alkali earth nitrates, alkaline earth metal halides, rare earth metal carbonates, transition metal carbonates, transition metal hydroxides, transition metal nitrates, transition metal halides, or a mixture of any two or more thereof, to generate an olefin-containing product stream; and collecting an olefin from the olefin-containing product stream; wherein the oxygen is fed with the carbon-containing feedstock in a gas stream comprising from greater than 0 wt % to about 21 wt % oxygen in an inert gas; and the process is conducted in the absence of a catalyst

Abstract: The invention provides compounds of formulae (I), or pharmaceutically acceptable salts and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors; as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit, CSF1R, and PDGFR (PDGFR?, PDGFR?) kinases.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the cellular entry of hepatitis B virus (HBV) and/or hepatitis D virus (HDV) or interfere with the function of the life cycle of HBV and/or HDV and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV and/or HDV infection. The invention also relates to methods of treating an HBV and/or HDV infection in a subject by administering a therapeutically effective amount of a compound of the present invention.

Abstract: The present disclosure relates to a heterogeneous catalyst composition comprising a metal catalyst chemically interacted with a micro-mesoporous aluminosilicate support. A process for catalytic oxidative dehydrogenation of hydrocarbons may include contacting, in a reactor system, a hydrocarbon-containing feedstock with the heterogeneous catalyst composition to generate olefinic compounds. A process for preparing a heterogeneous catalyst composition may include combining a micro-mesoporous aluminosilicate support with a metal catalyst precursor to form a catalyst precursor mixture, and heating the catalyst precursor mixture to a temperature of about 390° C. to about 750° C. to form a heterogeneous catalyst composition.

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention provides compounds of Formula (I), pharmaceutical compositions comprising these compounds and methods of using these compounds for treating a metabolic disease or liver condition. The present invention relates generally to compounds and pharmaceutical compositions useful as 17?-HSD13 inhibitors. Specifically, the present invention relates to compounds useful as inhibitors of 17?-HSD13 and methods for their preparation and use.

Abstract: This invention relates to a process for chemically treating a carbon-containing feedstock (e.g., a polymer-based feedstock), comprising contacting (e.g., by a hydrocracking reaction) the carbon-containing feedstock and a hydrogen stream in the presence of at least one hydrocracking catalyst to produce an alkane-containing product stream. The hydrocracking catalyst comprises at least one transition metal or transition metal sulfide supported on an oxide-containing support. This invention also relates to an alkane-containing mixture obtained by the process described herein and a system/apparatus for carrying out the process described herein.

Abstract: A heterogeneous catalyst composition including a metal and boron catalyst with boron dispersed in a molten matrix, where the molten matrix includes a eutectic mixture of alkali metal or alkaline earth metal salts or hydroxides. A process for preparing a heterogeneous catalyst composition, including combining a mixture of alkali metal or alkaline earth metal salts or hydroxides to form a matrix including a eutectic mixture, adding, to the matrix, a boron precursor and at least one metal catalyst precursor to form a catalyst precursor mixture, and heating the catalyst precursor mixture to a temperature of from 390° C. to 750° C. to form the heterogeneous catalyst composition. A process for catalytic oxidative dehydrogenation of hydrocarbons whereby a hydrocarbon-containing feedstock contacts the heterogeneous catalyst composition to generate olefinic compounds.

Abstract: The invention provides compounds of formulae (I), or pharmaceutically acceptable salts and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors; as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit, CSF1R, and PDGFR (PDGFR?, PDGFR?) kinases.

Abstract: The invention provides compounds of formulae (I), or pharmaceutically acceptable salts and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors; as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit, CSF1R, and PDGFR (PDGFR?, PDGFR?) kinases.

Abstract: A heterogeneous catalyst composition may include a metal catalyst supported on a porous mixed metal oxide support. A process for catalytic oxidative dehydrogenation of hydrocarbons may include contacting, in a reactor system, a hydrocarbon-containing feedstock with the heterogeneous catalyst composition to generate olefinic compounds. A process for preparing a heterogeneous catalyst composition may include combining a porous mixed metal oxide support with at least one metal catalyst precursor to form a catalyst precursor mixture, wherein the at least one metal catalyst precursor comprises at least one metal compound selected from the group consisting of transition metal compounds, rare-earth metal compounds, or a mixture thereof, and heating the catalyst precursor mixture to a temperature of about 390° C. to about 750° C. to form a heterogeneous catalyst composition.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, which inhibit the cellular entry of hepatitis B virus (HBV) and/or hepatitis D virus (HDV) or interfere with the function of the life cycle of HBV and/or HDV and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV and/or HDV infection. The invention also relates to methods of treating an HBV and/or HDV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the cellular entry of hepatitis B virus (HBV) and/or hepatitis D virus (HDV) or interfere with the function of the life cycle of HBV and/or HDV and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV and/or HDV infection. The invention also relates to methods of treating an HBV and/or HDV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: A process for the cracking of a carbon-containing feedstock to produce olefins, the process includes contacting, in a reactor system, the carbon-containing feedstock with a molten salt matrix consisting of a eutectic mixture of alkali metal carbonates, alkaline earth metal carbonates, or a mixture of any two or more thereof, to generate an olefin-containing product stream; and collecting an olefin from the olefin-containing product stream; wherein: the process is conducted in the absence of oxygen, and in the absence of a catalyst comprising a transition metal, a transition metal oxide, a rare-earth metal, a rare earth metal oxide, or a combination of any two or more thereof.

Abstract: A process for the cracking of a carbon-containing feedstock to produce olefins includes contacting, in a reactor system, the carbon-containing feedstock with oxygen gas in the presence of a molten salt matrix consisting of a eutectic mixture of alkali metal carbonates, alkaline earth metal carbonates, or a mixture of any two or more thereof, to generate an olefin-containing product stream; and collecting an olefin from the olefin-containing product stream; wherein: the oxygen is fed with the carbon-containing feedstock in a gas stream comprising from greater than 0 wt % to about 21 wt % oxygen in an inert gas; the process is conducted in the absence of a catalyst comprising a transition metal, a transition metal oxide, a rare-earth metal, a rare earth metal oxide, or a combination of any two or more thereof; and the process is conducted in the absence of a glass-forming oxide.

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the cellular entry of hepatitis B virus (HBV) and/or hepatitis D virus (HDV) or interfere with the function of the life cycle of HBV and/or HDV and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV and/or HDV infection. The invention also relates to methods of treating an HBV and/or HDV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.